Summit Therapeutics (SMMT) Profit After Tax (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Profit After Tax data on file, last reported at -$215.7 million in Q2 2026.

• Quarterly Profit After Tax rose 61.88% year-over-year to -$215.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$856.0 million (down 14.7% YoY) and the FY2025 annual result came in at -$1.1 billion, down 387.92% from the prior year.
• Profit After Tax eased to -$215.7 million in Q2 2026, from -$189.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$15.8 million in Q2 2023 to a low of -$565.9 million in Q2 2025.
• A 5-year average of -$133.4 million and a median of -$58.3 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax plunged 2242.17% — and 2024, when it soared 91.98%.
• Tracing SMMT's Profit After Tax over 5 years: stood at -$18.2 million in 2022, then sank by 101.5% to -$36.7 million in 2023, then slumped by 66.8% to -$61.2 million in 2024, then tumbled by 257.83% to -$219.0 million in 2025, then grew by 1.49% to -$215.7 million in 2026.
• The last three Profit After Tax figures came in at -$215.7 million (Q2 2026), -$189.4 million (Q1 2026), and -$219.0 million (Q4 2025), per Business Quant data.